Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation.

Autor: Petta TB; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.; Centro de Biociencias, Departmento de Biologia Celular e Genetica, Universidade Federal do Rio Grande do Norte, Natal CEP 59078-970, Brazil., Carlson J; Department of Pathology, City of Hope, Duarte, CA 91010, USA.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2024 Sep 27; Vol. 25 (19). Date of Electronic Publication: 2024 Sep 27.

Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.

Autor: Aoki D; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.; Akasaka Sanno Medical Center, International University of Health and Welfare Graduate School, Tokyo, Japan., Tabata T; Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan., Yanagida S; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan., Nakamura T; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima, Japan., Kondo E; Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Mie, Japan., Hamanishi J; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan., Harano K; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Hasegawa K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan., Hirasawa T; Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan., Hori K; Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan., Komiyama S; Department of Obstetrics and Gynecology, Toho University Faculty of Medicine, Tokyo, Japan., Matsuura M; Department of Obstetrics and Gynecology, Sapporo Medical University, Sapporo, Japan., Nakai H; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama, Japan., Nakamura H; Department of Obstetrics and Gynecology, Kure Medical Center and Chugoku Cancer Center, National Hospital Organization, Kure, Japan., Sakata J; Department of Gynecology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan., Takehara K; Department of Gynecologic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan., Takekuma M; Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan., Yokoyama Y; Department of Obstetrics and Gynecology, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan., Kase Y; Clinical Science, Oncology Cell Therapy and Therapeutic Area Unit, Takeda Pharmaceutical Company Limited, Osaka, Japan., Sumino S; Biostatistics, Japan Development Center, Takeda Pharmaceutical Company Limited, Osaka, Japan., Soeda J; Department of Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan., Kato A; Department of Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan., Suri A; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Okamoto A; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan. aikou7000@gmail.com., Sugiyama T; Department of Gynecology, St. Mary's Hospital, Fukuoka, Japan.

Publikováno v: Journal of gynecologic oncology [J Gynecol Oncol] 2024 Sep; Vol. 35 (5), pp. e114.

A Prostate-Specific Membrane Antigen-Targeting Small Molecule-Drug Conjugate Strategy to Overcome the Hematological Toxicity of Olaparib.

Autor: Chen Q; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China., Wu Z; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China., Zhu H; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.; School of Medicine, Hangzhou City University, Hangzhou 310015, China., Zhang X; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.; Jinhua Institute of Zhejiang University, Jinhua, Zhejiang 321299, China., Yu Y; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.; Jinhua Institute of Zhejiang University, Jinhua, Zhejiang 321299, China.; School of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang 830054, China., Chen W; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.; Jinhua Institute of Zhejiang University, Jinhua, Zhejiang 321299, China.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Nov 14; Vol. 67 (21), pp. 19586-19611. Date of Electronic Publication: 2024 Oct 31.

A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11).

Autor: Cho HW; Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea., Kim HS; Department of Obstetrics and Gynecology, Seoul National University, Seoul, South Korea., Park JY; Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea., Lee YY; Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Lim MC; Gynecologic Cancer Branch & Center for Uterine Cancer, National Cancer Center, Goyang, South Korea., Lee SJ; Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Min KJ; Department of Obstetrics and Gynecology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, South Korea., Eoh KJ; Department of Obstetrics and Gynecology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, South Korea., Lee KB; Department of Obstetrics and Gynecology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea., Kim MK; Department of Obstetrics and Gynecology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea., Song JY; Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea., Shim SH; Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, South Korea., Ji YI; Department of Obstetrics and Gynecology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea., Song YJ; Department of Obstetrics and Gynecology, Pusan National University College of Medicine, Busan, South Korea., Chang SJ; Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, South Korea., Kim MK; Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine, Seoul, South Korea., Abe A; Department of Gynecologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Kobayashi Y; Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan., Kajiyama H; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan., Shimada M; Department of Gynecology, Tohoku University Hospital, Sendai, Miyagi, Japan.; Department of Clinical Biobank, Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Miyagi, Japan., Okamoto A; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan., Ng JS; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, National University of Singapore, Singapore.; Gyn Cancer Program, National University Cancer Institute Singapore, Singapore., Lee JY; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea JUNGYUNLEE@yuhs.ac.

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Nov 04; Vol. 34 (11), pp. 1809-1812. Date of Electronic Publication: 2024 Nov 04.

Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA.

Autor: Liu Z; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China., Mao S; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China., Dai L; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China; School of Biological and Food Engineering, Huanghuai University, Zhumadian 463000, China., Huang R; Guangxi Key Laboratoryfor Pharmaceutical Molecular Discovery and Druggability Optimization, School of Pharmacy, Guilin Medicinal University, Guilin 541199, China., Hu W; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China., Yu C; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China., Yang Y; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China., Cao G; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China. Electronic address: CaoGuoxiu@126.com., Huang X; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China. Electronic address: viphuangxc@126.com.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2024 Nov 01; Vol. 113, pp. 117936. Date of Electronic Publication: 2024 Oct 05.